- Home
- RDZN vs IMUX Comparison
RDZN vs IMUX Comparison
Compare RDZN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- IMUX
- Stock Information
- Founded
- RDZN 2015
- IMUX 2016
- Country
- RDZN United States
- IMUX United States
- Employees
- RDZN N/A
- IMUX N/A
- Industry
- RDZN Blank Checks
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- RDZN Finance
- IMUX Health Care
- Exchange
- RDZN Nasdaq
- IMUX Nasdaq
- Market Cap
- RDZN 75.2M
- IMUX 85.8M
- IPO Year
- RDZN N/A
- IMUX N/A
- Fundamental
- Price
- RDZN $1.71
- IMUX $0.72
- Analyst Decision
- RDZN
- IMUX Strong Buy
- Analyst Count
- RDZN 0
- IMUX 5
- Target Price
- RDZN N/A
- IMUX $6.00
- AVG Volume (30 Days)
- RDZN 371.8K
- IMUX 1.1M
- Earning Date
- RDZN 11-14-2025
- IMUX 11-13-2025
- Dividend Yield
- RDZN N/A
- IMUX N/A
- EPS Growth
- RDZN N/A
- IMUX N/A
- EPS
- RDZN N/A
- IMUX N/A
- Revenue
- RDZN $48,035,296.00
- IMUX N/A
- Revenue This Year
- RDZN $38.45
- IMUX N/A
- Revenue Next Year
- RDZN $66.38
- IMUX N/A
- P/E Ratio
- RDZN N/A
- IMUX N/A
- Revenue Growth
- RDZN 3.42
- IMUX N/A
- 52 Week Low
- RDZN $0.68
- IMUX $0.56
- 52 Week High
- RDZN $2.99
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- RDZN 66.11
- IMUX 45.20
- Support Level
- RDZN $1.25
- IMUX $0.67
- Resistance Level
- RDZN $1.44
- IMUX $0.78
- Average True Range (ATR)
- RDZN 0.17
- IMUX 0.05
- MACD
- RDZN 0.02
- IMUX 0.00
- Stochastic Oscillator
- RDZN 93.00
- IMUX 40.15
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.